Alcohol Use DisorderNCT05747703
Telehealth Treatment for Alcohol Use Disorder
A study testing Ria Treatment Platform in people with Alcohol Use Disorder and Alcohol Dependence, run by Ria Health at 1 site in United States.
Trial summary
Participants with alcohol use disorder will be randomly assigned to either the Ria Treatment Platform or a waitlist control. The Ria Treatment Platform is a telehealth approach that incorporates medical assessment, medications for alcohol use disorder, individual and group coaching, educational video modules, and a… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Alcohol Use Disorder, Alcohol Dependence, Alcoholism
- What is being tested?
- Ria Treatment Platform
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 135 participants
- Where
- 1 siteUnited States
- Study dates
- 31 Jan 2024to Sep 2026
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- alcohol use disorder
Who cannot join
- inability to provide informed consent
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Telehealth Intervention to Increase Screening and Treatment for Alcohol Use Disorder
Participants with alcohol use disorder will be randomly assigned to either the Ria Treatment Platform or a waitlist control. The Ria Treatment Platform is a telehealth approach that incorporates medical assessment, medications for alcohol use disorder, individual and group coaching, educational video modules, and a Bluetooth-enabled breathalyzer. Patients are followed for three months during which data are collected, including measures of alcohol consumption and its consequences.
- Conditions
- Alcohol Use Disorder, Alcohol Dependence, Alcoholism
- Being tested
- Ria Treatment Platform
- Medical subject headings
- Alcoholism
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Ria Treatment PlatformCombination product
combined medication, coaching, education, and monitoring
| Study group | Role | What they receive |
|---|---|---|
| Ria Treatment Platfrom | Experimental | The Ria Treatment Platform is a telehealth approach that includes medical assessment, prescription of clinically appropriate medications for alcohol use disorder, individual and group coaching, educational video modules, and monitoring of breath alcohol concentrations through a Bluetooth-enabled breathalyzer. Receives: Combination Product: Ria Treatment Platform |
| waitlist control | No intervention | Patients in this arm will not be provided treatment during the study period. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percent of subjects without heavy drinking days
Heavy drinking is defined as 5 or more standard drinks per day for men and 4 or more standard drinks per day for women, as assessed by the Timeline Followback.
Measured: Final 4 weeks of the 12-week trial period
Secondary outcomes (2)
Proportion of abstinent days
Any drinking as assessed by the Timeline Followback
Measured: 12-week trial period
Liver function (ALT, AST, GGT)
Measures of liver function.
Measured: 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Feb 2023
- Study start31 Jan 2024
- Primary completion21 Apr 2026
- Study completionSep 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Alcohol Use DisorderStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- participants will be randomly assigned in a 1:1 to the Ria Treatment Platform or a waitlist control condition
- Masking
- None (open label)
- Enrolment
- 135 participants (actual)
Sponsor and investigators
- Lead sponsor
- Ria Health
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- National Institute on Alcohol Abuse and Alcoholism (NIAAA), Stanford University, University of Washington
- Responsible party
- Sponsor
- Investigators
- John Mendelson, MD, Principal investigator, Ria Health
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05747703
- Sponsor's protocol ID
- 1A
- Status last verified
- Jun 2026
- First submitted
- 17 Feb 2023
- Last updated
- 30 Jun 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No